Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target

Endeshaw Chekol Abebe,1 Teklie Mengie Ayele,2 Zelalem Tilahun Muche,3 Tadesse Asmamaw Dejenie4 1Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Eth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chekol Abebe E, Mengie Ayele T, Tilahun Muche Z, Asmamaw Dejenie T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	sars-cov-2 entry neuropilin 1 covid 19 therapeutic target Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/cfae77aa74634f528d01f2655df8fc29
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cfae77aa74634f528d01f2655df8fc29
record_format	dspace
spelling	oai:doaj.org-article:cfae77aa74634f528d01f2655df8fc292021-12-02T17:26:20ZNeuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target1177-5491https://doaj.org/article/cfae77aa74634f528d01f2655df8fc292021-05-01T00:00:00Zhttps://www.dovepress.com/neuropilin-1-a-novel-entry-factor-for-sars-cov-2-infection-and-a-poten-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Endeshaw Chekol Abebe,1 Teklie Mengie Ayele,2 Zelalem Tilahun Muche,3 Tadesse Asmamaw Dejenie4 1Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 3Department of Medical Physiology, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 4Department of Medical Biochemistry, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Endeshaw Chekol AbebeDepartment of Medical Biochemistry, College of Health Sciences, Debre Tabor University, PO Box: 272, Debre Tabor, 6300, Ethiopia, Tel +251 928428133Email endeshawchekole@gmail.comAbstract: The novel coronavirus disease 2019 (COVID-19) pandemic is severely challenging the healthcare systems and economies of the world, which urgently demand vaccine and therapy development to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, advancing our understanding of the comprehensive entry mechanisms of SARS-CoV-2, especially the host factors that facilitate viral infection, is crucial for the discovery of effective vaccines and antiviral drugs. SARS-CoV-2 has previously been documented to reach cells by binding with ACE2 and CD147 receptors in host cells that interact with the spike (S) protein of SARS-CoV-2. A novel entry factor, called neuropilin 1(NRP1), has recently been discovered as a co-receptor facilitating the entry of SARS-CoV-2. NRP1 is a single-pass transmembrane glycoprotein widely distributed throughout the tissues of the body and acts as a multifunctional co-receptor to bind with different ligand proteins and play diverse physiological roles as well as pathological and therapeutic roles in different clinical conditions/diseases, including COVID-19. The current review, therefore, briefly provides the overview of SARS-CoV-2 entry mechanisms, the structure of NRP1, and their roles in health and various diseases, as well as extensively discusses the current understanding of the potential implication of NRP1 in SARS-CoV-2 entry and COVID-19 treatment.Keywords: SARS-COV-2 entry, neuropilin 1, COVID-19, therapeutic targetChekol Abebe EMengie Ayele TTilahun Muche ZAsmamaw Dejenie TDove Medical Pressarticlesars-cov-2 entryneuropilin 1covid 19therapeutic targetMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 143-152 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	sars-cov-2 entry neuropilin 1 covid 19 therapeutic target Medicine (General) R5-920
spellingShingle	sars-cov-2 entry neuropilin 1 covid 19 therapeutic target Medicine (General) R5-920 Chekol Abebe E Mengie Ayele T Tilahun Muche Z Asmamaw Dejenie T Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
description	Endeshaw Chekol Abebe,1 Teklie Mengie Ayele,2 Zelalem Tilahun Muche,3 Tadesse Asmamaw Dejenie4 1Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 3Department of Medical Physiology, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 4Department of Medical Biochemistry, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Endeshaw Chekol AbebeDepartment of Medical Biochemistry, College of Health Sciences, Debre Tabor University, PO Box: 272, Debre Tabor, 6300, Ethiopia, Tel +251 928428133Email endeshawchekole@gmail.comAbstract: The novel coronavirus disease 2019 (COVID-19) pandemic is severely challenging the healthcare systems and economies of the world, which urgently demand vaccine and therapy development to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, advancing our understanding of the comprehensive entry mechanisms of SARS-CoV-2, especially the host factors that facilitate viral infection, is crucial for the discovery of effective vaccines and antiviral drugs. SARS-CoV-2 has previously been documented to reach cells by binding with ACE2 and CD147 receptors in host cells that interact with the spike (S) protein of SARS-CoV-2. A novel entry factor, called neuropilin 1(NRP1), has recently been discovered as a co-receptor facilitating the entry of SARS-CoV-2. NRP1 is a single-pass transmembrane glycoprotein widely distributed throughout the tissues of the body and acts as a multifunctional co-receptor to bind with different ligand proteins and play diverse physiological roles as well as pathological and therapeutic roles in different clinical conditions/diseases, including COVID-19. The current review, therefore, briefly provides the overview of SARS-CoV-2 entry mechanisms, the structure of NRP1, and their roles in health and various diseases, as well as extensively discusses the current understanding of the potential implication of NRP1 in SARS-CoV-2 entry and COVID-19 treatment.Keywords: SARS-COV-2 entry, neuropilin 1, COVID-19, therapeutic target
format	article
author	Chekol Abebe E Mengie Ayele T Tilahun Muche Z Asmamaw Dejenie T
author_facet	Chekol Abebe E Mengie Ayele T Tilahun Muche Z Asmamaw Dejenie T
author_sort	Chekol Abebe E
title	Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
title_short	Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
title_full	Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
title_fullStr	Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
title_full_unstemmed	Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target
title_sort	neuropilin 1: a novel entry factor for sars-cov-2 infection and a potential therapeutic target
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/cfae77aa74634f528d01f2655df8fc29
work_keys_str_mv	AT chekolabebee neuropilin1anovelentryfactorforsarscov2infectionandapotentialtherapeutictarget AT mengieayelet neuropilin1anovelentryfactorforsarscov2infectionandapotentialtherapeutictarget AT tilahunmuchez neuropilin1anovelentryfactorforsarscov2infectionandapotentialtherapeutictarget AT asmamawdejeniet neuropilin1anovelentryfactorforsarscov2infectionandapotentialtherapeutictarget
_version_	1718380813879345152

Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target

Ejemplares similares